MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 08-02-2023
Surface Oncology ROA Ratio 2011-2026 | SURF
Annual ROA Ratio Surface Oncology
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -39.76 | -41.12 | 27.33 | -41.6 | -3.79 | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 27.33 | -41.6 | -19.79 |
Quarterly ROA Ratio Surface Oncology
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -82.71 | -37.15 | -7.1 | -17.65 | -18.25 | -27.48 | -27.03 | 3.99 | 7.27 | 9.69 | 27.33 | -15.8 | -21.36 | -28.02 | -41.6 | -32.21 | -29.29 | -24.91 | -3.79 | -20.43 | -28.22 | -27.19 | -55.71 | -36.34 | -18.66 | -10.59 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 27.33 | -82.71 | -21.66 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
Ultragenyx Pharmaceutical
RARE
|
-37.53 | $ 19.23 | -3.85 % | $ 1.9 B |  USA |
 |
ARCA biopharma
ABIO
|
-21.14 | - | 1052.0 % | $ 415 M | USA |
 |
RedHill Biopharma Ltd.
RDHL
|
-53.95 | $ 0.8 | 0.89 % | $ 428 M |  Israel |
 |
Dr. Reddy's Laboratories Limited
RDY
|
6.49 | $ 13.56 | -1.56 % | $ 2.25 B |  India |
 |
Regeneron Pharmaceuticals
REGN
|
11.11 | $ 742.02 | -1.94 % | $ 77.6 B | USA |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-31.2 | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
-11.27 | - | -0.23 % | $ 916 M | USA |
 |
Replimune Group
REPL
|
-44.85 | $ 7.22 | -4.24 % | $ 582 M | USA |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M | France |
 |
REGENXBIO
RGNX
|
-42.8 | $ 7.88 | -4.6 % | $ 406 M | USA |
 |
Aileron Therapeutics
ALRN
|
-206.44 | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-78.56 | - | -6.81 % | $ 3.04 B | USA |
 |
Rigel Pharmaceuticals
RIGL
|
71.46 | $ 26.2 | -0.64 % | $ 471 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
-437.72 | - | -52.27 % | $ 4.45 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M | Israel |
 |
Atreca
BCEL
|
-62.67 | - | -11.76 % | $ 5.79 M | USA |
 |
Avidity Biosciences
RNA
|
-34.96 | $ 13.09 | -0.08 % | $ 1.8 B | USA |
 |
Acorda Therapeutics
ACOR
|
-232.99 | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
-34.23 | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
-13.29 | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
-41.82 | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-72.8 | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-225.71 | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Rhythm Pharmaceuticals
RYTM
|
-40.93 | $ 78.52 | -4.13 % | $ 5.1 B | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-11.6 | $ 12.57 | -9.96 % | $ 1.91 B | USA |
 |
Sana Biotechnology
SANA
|
-58.57 | $ 2.78 | -8.42 % | $ 704 M | USA |
 |
BeiGene, Ltd.
BGNE
|
3.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
SIGA Technologies
SIGA
|
10.61 | $ 5.35 | 7.76 % | $ 383 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
6.32 | $ 321.71 | -1.96 % | $ 42.1 B | USA |
 |
BioDelivery Sciences International
BDSI
|
26.14 | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
-94.17 | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-30.95 | - | - | $ 3.74 B | USA |
 |
Silence Therapeutics plc
SLN
|
-25.66 | $ 4.8 | -9.6 % | $ 622 M | Britain |
|
Enlivex Therapeutics Ltd.
ENLV
|
-54.23 | $ 1.08 | -0.92 % | $ 22.2 M | Israel |
 |
Enochian Biosciences
ENOB
|
-2162.69 | - | - | $ 40.5 M | USA |